HOUSTON

休斯顿

,

，

July 21, 2026

2026年7月21日

/PRNewswire/ -- TYBR Health today announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL® System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery..

/PRNewswire/ -- TYBR Health 今日宣布完成由 Vensana Capital 和 Mutual Capital Partners 领投，Neovate Capital Partners 及现有投资者参投的 3,000 万美元 A 轮融资。该公司将利用这笔资金扩大其获美国食品药品监督管理局（FDA）许可的 B3 GEL® 系统的商业覆盖范围，拓展产品适应症，并开展评估骨科手术中组织保护效果的临床研究。

Continue Reading

继续阅读

B3 GEL™ delivers clinical improvement in post-operative tendon mobility through an intuitive and precise proprietary delivery system, empowering surgeons to achieve superior functional outcomes with seamless integration into existing surgical workflows

B3 GEL™ 通过直观且精准的专有递送系统，改善术后肌腱活动度，帮助外科医生在无缝融入现有手术流程的同时，实现更优的功能性疗效。

Speed

速度

Speed

速度

Orthopedic surgery is very good at what it sets out to do: restore anatomy and repair damaged structures. The operation, though, is only the start of recovery. How tissue responds over the following days and weeks shapes scarring, mobility, pain, and how much function returns, and surgeons have had few tools to influence tissue healing after the surgery..

骨科手术在实现其既定目标方面非常出色，即恢复解剖结构并修复受损组织。然而，手术只是康复的开始。在接下来的几天和几周内，组织的反应方式会影响疤痕形成、活动能力、疼痛程度以及功能恢复的程度，而外科医生在术后影响组织愈合方面的工具却寥寥无几。

TYBR Health builds technology for that critical healing window. The B3 GEL® System is a flowable extracellular matrix hydrogel, cleared by the FDA, designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal.

TYBR Health 为这一关键愈合窗口期开发技术。B3 GEL® 系统是一种可流动的细胞外基质水凝胶，已获得美国食品药品监督管理局（FDA）批准，旨在在肌腱、韧带、肌肉及周围软组织愈合过程中为其提供保护。

'Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed,' said Tim Keane, PhD, co-founder and CEO of TYBR Health. 'We built TYBR Health around a simple principle: managing the healing environment should complement good surgical technique and contribute to better recovery for patients.'.

“外科医生在结构修复方面非常出色，但随后的生物学过程才是决定愈合效果的关键。而这一关键因素长期以来却 largely 被忽视。”TYBR Health 的联合创始人兼首席执行官蒂姆·基恩博士表示。“我们创立 TYBR Health 基于一个简单的原则：管理愈合环境应与良好的手术技术相辅相成，从而促进患者更好地康复。”

'There's a shift underway across surgical specialties, from focusing almost entirely on the mechanical repair to also weighing the biological conditions that repair needs to succeed,' Keane added. 'This financing lets us reach more surgeons and generate the clinical evidence to move that shift forward.'.

基恩补充道：“目前，各个外科专业领域正在发生转变，从几乎完全专注于机械性修复，转向同时考量修复成功所需的生物学条件。这笔融资使我们能够接触更多外科医生，并生成推动这一转变所需的临床证据。”

Since launch, the B3 GEL® System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures. Early adoption has come from surgeons looking for a straightforward way to manage and protect healing tissue without adding time or complexity to the case.

自推出以来，B3 GEL® 系统已应用于手、腕、肩、足踝以及运动医学手术中。早期采用该系统的外科医生旨在寻找一种简便的方法，以在不增加手术时间或复杂性的前提下，有效管理和保护愈合中的组织。

'B3 GEL® adheres where it's applied, conforms to the native anatomy, and forms a protective barrier through the healing window,' said Greg Banker, Partner at Vensana Capital. 'TYBR has shown real commercial traction early and built a strong team, and we're glad to back them in this next phase.'

“B3 GEL® 能够在施用部位牢固粘附，贴合天然解剖结构，并在愈合窗口期形成保护屏障，”Vensana Capital 合伙人 Greg Banker 表示。“TYBR 在早期已展现出真正的商业势头，并组建了一支强大的团队，我们很高兴在这一下一阶段为其提供支持。”

'TYBR Health is addressing a gap surgeons have lived with for a long time, with a product that fits the way they already work,' said Liz Todia Zambory, Principal at Mutual Capital Partners. 'We're excited to co-lead this round and support the company's growth.'

“TYBR Health 正在解决外科医生长期以来面临的一个空白，其产品契合他们现有的工作方式，” Mutual Capital Partners 的负责人 Liz Todia Zambory 表示。“我们很高兴能共同领投本轮融资，并支持公司的成长。”

As part of the financing, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR Health Board of Directors, alongside independent director Aaron Smith.

作为融资安排的一部分，Vensana Capital 的 Greg Banker 和 Mutual Capital Partners 的 Liz Todia Zambory 将加入 TYBR Health 董事会，与独立董事 Aaron Smith 一同任职。

About the B3 GEL® System

关于 B3 GEL® 系统

The B3 GEL® System is an FDA-cleared, flowable extracellular matrix hydrogel designed to protect healing tendons, ligaments, muscles, and surrounding soft tissues following orthopedic surgery. Unlike sheet-based barriers, B3 GEL® conforms to complex three-dimensional anatomy and can be rapidly applied within existing surgical workflows.

B3 GEL® 系统是一种获美国食品药品监督管理局（FDA）许可的可流动细胞外基质水凝胶，旨在保护骨科手术后愈合中的肌腱、韧带、肌肉及周围软组织。与片状屏障不同，B3 GEL® 能够贴合复杂的三维解剖结构，并可在现有手术流程中快速应用。

By combining practical surgical handling with biologically derived extracellular matrix technology, TYBR Health is working to advance a new standard for protecting tissues during recovery from orthopedic procedures..

TYBR Health 将实用的手术操作技术与生物来源的细胞外基质技术相结合，致力于推进骨科手术后组织保护的新标准。

About TYBR Health

关于TYBR健康

TYBR Health is a medical technology company developing products designed to improve healing and recovery following surgery. The company's extracellular matrix technology platform is intended to provide surgeons with practical tools for protecting healing tissues and managing the healing environment following surgical repair.

TYBR Health 是一家医疗科技公司，致力于开发旨在改善术后愈合与恢复的产品。该公司的细胞外基质技术平台旨在为外科医生提供实用工具，以保护愈合中的组织并管理手术修复后的愈合环境。

TYBR Health is headquartered in Houston, Texas..

TYBR Health 总部位于德克萨斯州休斯顿。

About Vensana Capital

关于 Vensana Capital

Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Founded in 2019, Vensana has approximately $1 billion in capital under management and is actively investing in development and commercial-stage companies across the medtech sector, including medical devices, data science-oriented solutions, life science tools & diagnostics, and tech-enabled services.

Vensana Capital 是一家风险投资和成长型股权投资公司，致力于与那些希望通过医疗技术领域的突破性创新来变革医疗保健的创业者合作。Vensana 成立于 2019 年，管理资本约 10 亿美元，积极投资于医疗技术领域处于开发和商业化阶段的公司，包括医疗器械、数据科学导向解决方案、生命科学工具与诊断以及技术赋能服务。

Vensana's investment team has a history of successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. .

Vensana的投资团队拥有与行业领先企业背后的创业者成功合作的历史，这些企业包括Artelon、Cameron Health、CardiAQ、Cartiva、CV Ingenuity、Epix Therapeutics、Inari Medical、Intact Vascular、Lutonix、Neuwave Medical、Personal Genome Diagnostics、Relievant Medsystems、Sequent Medical、Topera、Ulthera、Veran Medical Technologies、Vertiflex和Vesper Medical。

http://www.vensanacap.com

http://www.vensanacap.com

About Mutual Capital Partners

关于 Mutual Capital Partners

Mutual Capital Partners is a Cleveland, Ohio-based venture capital firm dedicated to partnering with entrepreneurs who are transforming healthcare through innovative technologies. Founded in 2005, Mutual Capital Partners invests in strong, mission-driven teams commercializing medical device and healthcare IT solutions that improve patient outcomes, with a focus on companies located outside the major coastal tech hubs.

Mutual Capital Partners 是一家总部位于俄亥俄州克利夫兰的风险投资公司，致力于与通过创新技术变革医疗保健的创业者合作。该公司成立于2005年，专注于投资那些正在商业化医疗器械和医疗保健IT解决方案、以改善患者预后为使命的强大团队，并特别关注位于主要沿海科技中心之外的企业。

Mutual Capital Partners' investment team has a history of successfully partnering with entrepreneurs behind industry-leading companies, including recent exits SPR Therapeutics, eBlu Solutions, as well as OrthoHelix, Cleveland Heartlab, TFX Medical, RevLocal, and Cardinal Commerce. .

Mutual Capital Partners 的投资团队拥有与行业领先企业背后的创业者成功合作的历史，包括最近的退出案例 SPR Therapeutics 和 eBlu Solutions，以及 OrthoHelix、Cleveland Heartlab、TFX Medical、RevLocal 和 Cardinal Commerce。

www.mutualcapitalpartners.com

www.mutualcapitalpartners.com

About Neovate Capital Partners

关于 Neovate Capital Partners

Neovate Capital Partners is a global, surgery-focused life science investment firm backing transformational medical technology and select category-defining therapeutics at their critical pre-inflection points. Neovate's partners are seasoned operators and sub-sector experts who work alongside founders — spending real time with CEOs, boards, and leadership teams to guide and de-risk the most meaningful milestones.

Neovate Capital Partners 是一家全球性的、专注于外科领域的生命科学投资公司，致力于在关键转折前夕支持具有变革意义的医疗技术和少数定义品类的治疗产品。Neovate 的合伙人是经验丰富的运营专家和细分领域专家，他们与创始人并肩合作，投入大量时间与首席执行官、董事会及领导团队密切协作，以指导并降低最关键里程碑节点的风险。

Through its strategic partnership with Precision Life Science Partners, Neovate extends that hands-on model with a network of more than 70 specialists drawn from the world's leading medtech and biopharma companies, giving every portfolio company operating depth well beyond a typical early-stage investor.

通过与Precision Life Science Partners的战略合作，Neovate将这一实操模式进一步拓展，依托一个由来自全球领先医疗科技和生物制药公司的70多位专家组成的网络，为每家投资组合公司提供远超典型早期投资者的运营深度。

Neovate's partners have a history of backing category-defining companies, including Biorez, Avisi, Nanochon, Orthotaxy, Peca Labs, Peptilogics, Restor3D, Verademics, Ocugenix, Phoenix Kinetics, and RevMedica. .

Neovate的合作伙伴拥有支持定义行业类别的公司的悠久历史，其中包括Biorez、Avisi、Nanochon、Orthotaxy、Peca Labs、Peptilogics、Restor3D、Verademics、Ocugenix、Phoenix Kinetics和RevMedica。

www.neovate.vc

www.neovate.vc

Media Contact

媒体联系人

Tim Keane

蒂姆·基恩

Co-founder and CEO

联合创始人兼首席执行官

TYBR Health

TYBR健康

[email protected]

[email protected]

SOURCE TYBR Health

来源 TYBR Health

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示